天潤曲軸(002283.SZ)擬註銷30.325萬份股票期權
格隆匯1月6日丨天潤曲軸(002283.SZ)公佈,公司股票期權激勵計劃首次授予股票期權第一個行權期行權期限自2015年12月28日至2019年12月25日止,截至上述行權期限屆滿之日,尚有17名激勵對象持有的30.325萬份股票期權未行權,根據《上市公司股權激勵管理辦法》、《中小企業板信息披露業務備忘錄第4號:股權激勵》、公司《股票期權激勵計劃》和《股票期權激勵計劃考核管理辦法》的相關規定,以及公司2014年第一次臨時股東大會的授權,公司董事會同意註銷首次授予股票期權第一個行權期已到期未行權的股票期權30.325萬份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.